Investigation on the mechanisms of action of aprotinin in cardiac surgery [PDF]
Baranky, A.+8 more
core +1 more source
PI3Kδ Inhibitor Parsaclisib in Japanese Patients With Relapsed or Refractory Follicular Lymphoma
CITADEL‐213 evaluated the efficacy and safety of parsaclisib (PI3Kδ inhibitor) in Japanese patients with relapsed or refractory follicular lymphoma (R/R FL). The objective response rate was 88.1%, with 23.8% of patients experiencing a complete response and 64.3% experiencing a partial response; treatment‐emergent adverse events led to parsaclisib ...
Noriko Fukuhara+15 more
wiley +1 more source
Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors. [PDF]
Hu H, Lei D, Liang Y.
europepmc +1 more source
We report an individual with mucopolysaccharidosis type IIIB and chronic pancytopenia. Hematological studies in a mouse model revealed microcytic anemia and decreased monocyte count. Hence, pancytopenia is thought to be secondary to mucopolysaccharidosis type IIIB, and we suggest that a complete blood count should be included in the clinical ...
Éliane Beauregard‐Lacroix+3 more
wiley +1 more source
Romiplostim Reduces Platelet Transfusion Needs in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. [PDF]
Surya Prakash V+14 more
europepmc +1 more source
Post-transfusion purpura as the main manifestation of a trilineal transfusion reaction, responsive to steroids: flow-cytometric investigation of granulocyte and platelet antibodies [PDF]
Noemí Puig+4 more
openalex +1 more source
ABSTRACT Background Paroxysmal nocturnal haemoglobinuria (PNH) is an ultra‐rare, acquired non‐malignant haematological disorder characterised by thrombosis risk, serious complications and debilitating symptoms in untreated patients. Objective This anchored indirect treatment comparison (ITC) evaluated efficacy data between proximal complement 3 ...
Regis Peffault de Latour+9 more
wiley +1 more source
Efficacy and Safety of Bendamustine‐Rituximab for Nodular Lymphocyte Predominant Hodgkin Lymphoma
ABSTRACT Introduction Bendamustine‐rituximab (BR) has demonstrated efficacy and tolerability in the treatment of various indolent B‐cell lymphomas, but there is limited data regarding its outcomes in nodular lymphocyte predominant B‐cell (Hodgkin) lymphoma (NLPBL).
Alexander Robin+6 more
wiley +1 more source
Cumulative donor-specific antibody threshold predicts platelet transfusion response in HLA-alloimmunized patients. [PDF]
Boothby AB+17 more
europepmc +1 more source